- Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021
- As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program
- Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics
Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases.
As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic substance – in order to develop clinical-stage compounds for diseases with high unmet medical needs, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)
is the perfect candidate to participate in psychedelics events.
In a recent press release (https://ibn.fm/Z8Ify
), Tryp announced it would present at one such event: the virtual Psychedelics in Psychiatry and Beyond Conference slated for Thursday, June 17, 2021, and sponsored by H.C. Wainwright & Co., one of America’s oldest and most trusted investment banks focused on equity research and capital market activity.
As part of Tryp’s presentation to be made available on-demand from 7 a.m. EDT on the day of the conference, Chairman and CEO Greg McKee will offer insight into the company’s business as well as its research-backed pipeline, including the proprietary Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program.
The PFN program is Tryp’s psychedelics-centered drug development platform targeting certain neuropsychiatric disorders, including fibromyalgia, chronic pain, and eating disorders. The program’s lead drug candidate, TRP-8802, is expected to proceed directly to Phase 2a clinical trials as Tryp intends to leverage existing preclinical and clinical data from the expansive body of research on the active pharmaceutical ingredients in TRP-8802. This approach is expected to accelerate the drug development process toward ultimate approval by the US Food and Drug Administration (“FDA”).
The company intends to further expand research into other indications for psilocybin that, up until this point, have received little attention from pharmaceutical companies. By collaborating with multiple academic institutions and leading principal investigators, Tryp expects to develop new novel treatments, thereby addressing the significant unmet medical needs.
Designed for public and private companies, industry executives, business development executives, venture capitalists, private equity firms, and institutional investors, the conference will feature company presentations, one-on-one investor meetings, and networking opportunities. Attendees should look forward to gaining a deep understanding of psychedelics and the future of this vital class of compounds in psychiatric applications as well as other uses.
Tryp will present alongside other leading pharmaceutical companies currently building a robust R&D pipeline of psychedelic-assisted therapeutics. These include Mindset Pharma Inc. (https://ibn.fm/kUTKb
) and Mydecine Innovations Group (https://ibn.fm/178sr
), among others.
To register for the event, attendees can use the following link: https://ibn.fm/5uuv1
For more information, visit the company’s website at www.TrypTherapeutics.com
NOTE TO INVESTORS:
The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks
designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
San Francisco, California
PsychedelicNewsWire is part of the InvestorBrandNetwork